Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

Compare

650 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMLX Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Amylyx

Pharmaceuticals Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMLX Stock 12 Month Forecast

Average Price Target

$20.14

▲(70.25% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc in the last 3 months. The average price target is $20.14 with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 70.25% change from the last price of $11.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,13.073846153846153,14.067692307692308,15.061538461538461,16.055384615384614,17.049230769230768,18.043076923076924,19.036923076923078,20.03076923076923,21.024615384615384,22.018461538461537,23.012307692307694,24.006153846153843,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,12.7,13.32,13.94,14.56,15.18,15.8,16.42,17.04,17.66,18.28,18.9,19.52,{"y":20.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.08,12.304615384615385,12.52923076923077,12.753846153846155,12.978461538461538,13.203076923076923,13.427692307692308,13.652307692307692,13.876923076923077,14.10153846153846,14.326153846153847,14.55076923076923,14.775384615384615,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$20.14

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rami Katkhuda

LifeSci Capital

$24

Buy

102.87%

Upside

Reiterated

01/09/26

Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support UpsideWe recently hosted a live call with a KOL who treats ~500 PBH paen ts and serves as at her instuon to discuss the disease burden, current treatment landscape, and clinical potenal of avexide in post-bariatric hypoglycemia; key takeaways from our discussion can be found below. The KOL emphasizes that PBH can signiﬁcantly impair day-to-day acvies and may be life- threatening/require hospitalizaon in severe cases. Moreover, she esma tes that approximately 50% of PBH paen ts remain inadequately controlled despite dietary intervenon + oﬀ-label pharmacologic therapy and experience an “atrocious” quality of life, underscoring the need for novel therapies. As a reminder, Amylyx (Nasdaq: AMLX) expects to complete enrollment of the Phase III LUCIDITY trial, evaluang the safety/eﬃcacy of 90mg SC QD avexide vs. placebo in 75 paen ts with PBH following with topline data ancipa ted in Q3 2026.

Graig Suvannavejh

Mizuho Securities

$18

Buy

52.16%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Geoff Meacham

Citi

$20

Buy

69.06%

Upside

Reiterated

01/05/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Tim Anderson

Bank of America Securities

$16→$15

Buy

26.80%

Upside

Reiterated

12/18/25

Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Seamus Fernandez

Guggenheim

$25

Buy

111.33%

Upside

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and PACS Group Inc (NYSE: PACS)

Andrew Fein

H.C. Wainwright

$16→$20

Buy

69.06%

Upside

Reiterated

11/10/25

Amylyx price target raised to $20 from $16 at H.C. WainwrightAmylyx price target raised to $20 from $16 at H.C. Wainwright

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/06/25

Buy Rating for Amylyx Pharmaceuticals: Promising Phase III Study and Market Potential for Avexitide

Joel Beatty

Robert W. Baird

$10→$19

Buy

60.61%

Upside

Reiterated

10/16/25

Amylyx price target raised to $19 from $10 at BairdAmylyx price target raised to $19 from $10 at Baird

Marc Goodman

Leerink Partners

$10→$20

Buy

69.06%

Upside

Reiterated

10/07/25

Leerink Partners Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Corinne Johnson

Goldman Sachs

$10→$20

Buy

69.06%

Upside

Reiterated

09/16/25

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rami Katkhuda

LifeSci Capital

$24

Buy

102.87%

Upside

Reiterated

01/09/26

Graig Suvannavejh

Mizuho Securities

$18

Buy

52.16%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Geoff Meacham

Citi

$20

Buy

69.06%

Upside

Reiterated

01/05/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Tim Anderson

Bank of America Securities

$16→$15

Buy

26.80%

Upside

Reiterated

12/18/25

Bank of America Securities Keeps Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Seamus Fernandez

Guggenheim

$25

Buy

111.33%

Upside

Reiterated

12/11/25

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) and PACS Group Inc (NYSE: PACS)

Andrew Fein

H.C. Wainwright

$16→$20

Buy

69.06%

Upside

Reiterated

11/10/25

Amylyx price target raised to $20 from $16 at H.C. WainwrightAmylyx price target raised to $20 from $16 at H.C. Wainwright

Joseph Thome

TD Cowen

Buy

―

Reiterated

11/06/25

Buy Rating for Amylyx Pharmaceuticals: Promising Phase III Study and Market Potential for Avexitide

Joel Beatty

Robert W. Baird

$10→$19

Buy

60.61%

Upside

Reiterated

10/16/25

Amylyx price target raised to $19 from $10 at BairdAmylyx price target raised to $19 from $10 at Baird

Marc Goodman

Leerink Partners

$10→$20

Buy

69.06%

Upside

Reiterated

10/07/25

Leerink Partners Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)

Corinne Johnson

Goldman Sachs

$10→$20

Buy

69.06%

Upside

Reiterated

09/16/25

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amylyx Pharmaceuticals Inc

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

-0.14%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of -0.14% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+25.86%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +25.86% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

15/20 ratings generated profit

Average Return

+91.60%

reiterated a buy rating 2 months ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +91.60% per trade.

2 Years

xxx

Success Rate

15/20 ratings generated profit

Average Return

+181.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +181.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMLX Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMLX has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the past 3 months is 20.14.

Each month's total comprises the sum of three months' worth of ratings.

AMLX Financial Forecast

AMLX Earnings Forecast

Next quarter’s earnings estimate for AMLX is -$0.35 with a range of -$0.47 to -$0.14. The previous quarter’s EPS was -$0.37. AMLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.

AMLX Sales Forecast

Next quarter’s sales forecast for AMLX is -$52.00K with a range of -$416.00K to $0.00. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AMLX has Performed in-line its overall industry.

AMLX Stock Forecast FAQ

What is AMLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Amylyx Pharmaceuticals Inc’s 12-month average price target is 20.14.

What is AMLX’s upside potential, based on the analysts’ average price target?

Amylyx Pharmaceuticals Inc has 70.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMLX a Buy, Sell or Hold?

Amylyx Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Amylyx Pharmaceuticals Inc’s price target?

The average price target for Amylyx Pharmaceuticals Inc is 20.14. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $15.00. The average price target represents 70.25% Increase from the current price of $11.83.

What do analysts say about Amylyx Pharmaceuticals Inc?

Amylyx Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of AMLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

AMLX Analyst Ratings

AMLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amylyx Pharmaceuticals Inc

AMLX Analyst Recommendation Trends

AMLX Financial Forecast

AMLX Earnings Forecast

AMLX Sales Forecast

AMLX Stock Forecast FAQ

Detailed List of Analyst Forecasts